About Reaction Biology
Reaction Biology Corporation is an industry leader and innovator specializing in assay services for early-stage drug discovery. Founded in 2001, Reaction Biology offers a wide range of services, including robust assay technologies for kinase and epigenetic biochemical and cell-based high throughput screening (HTS) and selectivity compound profiling. We also offer relevant HTS assay reagents, including highly purified and characterized epigenetic proteins. On average, several million HTS and profiling reactions are performed per year. Over 750 companies worldwide, including pharmaceutical, biotech, academic, and nonprofit laboratories, utilize our biochemical and cellular assay services and purchase epigenetic proteins.
Matt Oristano- CEO/President
Mr. Oristano is President of Alda Inc, a private investment firm. In addition, he serves on the board of Spōk (Nasdaq: SPOK) and its audit committee. He is also on the board of Crystalplex Corporation. From 1993 to 1999, Mr. Oristano was Chairman and CEO of People's Choice TV Corp, a public wireless TV and internet company, which he founded in 1988 and sold to Sprint in 1999. Mr. Oristano has a degree in physics from Rennselaer Polytechnic Institute.
Tom Petzinger, Jr.
Mr. Petzinger is CEO of LaunchCyte, a biotechnology development firm. Mr. Petzinger also serves as Chairman of Immunetrics Inc., Crystalplex Corp, Proteopure Inc., and Knopp Neurosciences. Prior to co-founding LaunchCyte, he spent 22 years at The Wall Street Journal, where he served as Washington economics editor, deputy Washington bureau chief, millennium editor, and weekly columnist. A Pulitzer nominee for numerous investigative stories, he has also written three best-selling business books. He received his B.S. in Journalism from Northwestern University, where he was a Richter International Scholar.
Based in New York City, Mr. Kramer has had long experience advising firms and governments worldwide on financial transactions totaling hundreds of billions of dollars. He is currently the Founding Partner of Ducera Partners LLC. Previously, he has been a senior partner at Perella Weinberg Partners, a member of the Management Committee at Greenhill & Co, and head of M&A and Financial Restructuring for the firm of Houlihan Lokey Howard & Zukin.
Jonathan Kaufman, PhD
Dr. Kaufman is the CEO of Lipella Pharmaceuticals, Inc. Prior to co-founding Lipella, Dr.Kaufman was Vice President and Chief Science Officer of LaunchCyte LLC, a biotechnology corporate incubator. At LaunchCyte, Dr. Kaufman was co-founder of Proteopure Inc. and Knopp Neuroscience Inc.; served as the founding President of Crystalplex Corp.; served on the Boards of Reaction Biology Corp., Crystalplex Corp., and Immunetrics Inc.; and served as Secretary of Reaction Biology Corp. Prior to joining LaunchCyte, Dr. Kaufman served on the New Technology Committee in the Chemical Manufacturing Division of Merck& Co., and also served as a consultant to GlaxoSmithKline in the department of bioinformatics. Dr. Kaufman received his MBA in Finance from the Wharton School, and his PhD in Biophysics from the University of Pennsylvania School of Medicine.
Haiching Ma, PhD
Dr. Ma is the Chief Science Officer of RBC, where he developed and implemented the current RBC technology and service platforms. Dr. Ma is the Principal Investigator for multiple SBIR awards and an RO1 award from NIH all RBC totaling over 7 million dollars, and which cover research topics including assay development for human kinome and epigenome targets, toxicity predictions, chemical microarray HTS and cell death prevention that reduce side effects from radiation therapies. Dr. Ma received his Ph.D. in Pharmacology from the Medical School of The University of Pennsylvania and continued his postdoc training there in the Institute for Medicine and Engineering.
Scott Diamond, PhD
Dr. Diamond is the scientific founder of RBC, he is the founding director of the Penn Center for Molecular Discovery. He holds the Arthur E. Humphrey Chair of Chemical and Biomolecular Engineering. Dr. Diamond researches biotechnologies in several key areas: endothelial mechanobiology, blood clot dissolving therapies, blood coagulation, nonviral gene therapy, proteomics, and high throughput drug discovery. He has produced over 120 publications and patents and has served on advisory committees to NSF, NIH, AHA, and NASA, and has consulted extensively for industry and government. Diamond is the recipient of the NSF National Young Investigator Award, the NIH FIRST Award, the American Heart Association Established Investigator Award, the AIChE Allan P. Colburn Award, and the George Heilmeier Excellence in Research Award. Dr. Diamond is an elected Fellow of the Biomedical Engineering Society (BMES). Currently, Dr. Diamond is the Director of the Penn Biotechnology Masters Program, one of the largest in the country with more than 130 students. Dr. Diamond also serves as Associate Director of the Institute for Medicine and Engineering (IME). He received his bachelor’s degree in chemical engineering in 1986 from Cornell University and his PhD from Rice University in 1990.
John McCall, PhD
Dr. McCall is the President of PharMac LLC, and a Senior Consultant in areas of drug discovery, project management, project evaluation, and research organization. He chairs an NINDS (National Institute of Neurological Disorders and Stroke) Development Team investigating new therapies for spinal muscular atrophy, and is a member of nine scientific advisory boards. He has over 50 patents and 55 journal publications. Previously he was Vice President of Pfizer Global Research and Development and a member of the Pfizer Global Technology Board. At Pharmacia Dr. McCall was Global Vice President of Discovery Chemistry with responsibility for Structural and Analytical Chemistry, Medicinal and Combinatorial Chemistry, Computational Chemistry, Cheminformatics, and managed a global staff of 570.
Haiching Ma, PhD
Kurumi Horiuchi, PhD
Director of Biochemistry
Yuren Wang, PhD
Director of Pharmacology & QC
Konrad Howitz, PhD
Director of Epigenetics
Ekaterina Kuznetsova, PhD
Director of Product Development
Kelvin Lam, PhD
Director of Strategic Partnerships
Director of Human Resources
Financial Conflict of Interest Policy